FREQUENCY OF DETECTION OF ANTIBODIES TO HEPATITIS C VIRUS AMONG CONVENTIONALLY HEALTHY POPULATION OF RUSSIAN FEDERATION

Cover Page


Cite item

Full Text

Abstract

Aim. Determine the prevalence of antibodies to hepatitis C virus (anti-HCV) among conditionally healthy population of Russian Federation. Materials and methods. Sera samples obtained from conditionally healthy population of the Russian Federation from 5 geographically distant regions with different levels of morbidity for hepatitis C were studied: Sverdlovsk, Rostov, Moscow regions, Tyva and Sakha (Yakutia) Republics. 4764 samples were studied in total obtained from individuals of 10 age groups: younger than 1, 1 - 4, 5 - 9, 10 - 14,15 - 19, 20 - 29, 30 - 39, 40 - 49,50 - 59, olderthan 60 years. Anti-HCV were determined by commercial ELISA. Results. The total prevalence of anti-HCV in 5 regions of Russian Federation was 2.6% (126/4764). The highest frequency of detection of anti-HCV was detected in Tyva and Yakutia Republics and was 3.3%, in other regions this parameter varied from 1,7 (Moscow region) to 3% in Sverdlovsk region. Peak parameters of anti-HCV detection among population in various regions were connected with various age groups: olderthan 60 years in Tyva and Yakutia Republics (11 and 9.9%, respectively), 40 - 49 in Moscow region (6.2%), 1 - 4 and 30 - 39 years in Sverdlovsk region (5.9 and 4.9%, respectively) and 20 - 39 in Rostov region (3.9%). Conclusion. Results of anti-HCV detection in various age cohorts of conditionally healthy population of Russian Federation give evidence regarding high morbidity with HCV of almost all the age groups in the interval from 20 to older than 60 years. Age cohorts were detected in each of the studied regions for which inclusion into regional screening programs is feasible.

About the authors

N. V. Soboleva

Chumakov Institute of Poliomyelitis and Viral Encephalitides

Author for correspondence.
Email: noemail@neicon.ru
Russian Federation

A. A. Karlsen

Russian Medical Academy of Continuous Professional Education, Mechnikov Research Institute of Vaccines and Sera

Email: noemail@neicon.ru
Russian Federation

T. V. Kozhanova

Chumakov Institute of Poliomyelitis and Viral Encephalitides,Scientific-Practical Centre of Medical Aid to Children with Development Diseases of Maxillofacial Region and Congenital Diseases of the Nervous System

Email: noemail@neicon.ru
Russian Federation

V. S. Kichatova

Russian Medical Academy of Continuous Professional Education, Mechnikov Research Institute of Vaccines and Sera

Email: noemail@neicon.ru
Russian Federation

V. V. Klushkina

Sechenov First Moscow State Medical University

Email: noemail@neicon.ru
Russian Federation

O. V. Isaeva

Russian Medical Academy of Continuous Professional Education, Mechnikov Research Institute of Vaccines and Sera

Email: noemail@neicon.ru
Russian Federation

M. E. Ignatyeva

Administration of Rospotrebnadzor for the Sakha (Yakutia) Republic

Email: noemail@neicon.ru
Russian Federation

VV. .. Romanenko

Centre for Hygiene and Prophylaxis for Sverdlovsk Region

Email: noemail@neicon.ru
Russian Federation

N. D. Oorzhak

infectious Hospital

Email: noemail@neicon.ru
Russian Federation

E. Yu. Malinnikova

Russian Medical Academy of Continuous Professional Education, Mechnikov Research Institute of Vaccines and Sera

Email: noemail@neicon.ru
Russian Federation

K. K. Kyuregyan

Russian Medical Academy of Continuous Professional Education, Mechnikov Research Institute of Vaccines and Sera

Email: noemail@neicon.ru
Russian Federation

M. I. Mikhaylov

Russian Medical Academy of Continuous Professional Education, Mechnikov Research Institute of Vaccines and Sera

Email: noemail@neicon.ru
Russian Federation

References

  1. Вирусные гепатиты в Российской Федерации. Под ред. В.И.Покровского, А.Б.Жебруна. СПб, ФБУН НИИЭМ им. Пастера, 2013.
  2. Рекомендации по диагностике и лечению взрослых больных гепатитом С. Министерство здравоохранения Российской Федерации. 2013 год. http://gepatit-c.ru/treatment/pdf/ hcv_rek_2013.pdf.
  3. Armstrong G.L., Wasley A., Simard Е.Р. et al. The prevalence of hepatitis C virus infection in the United States, 1999 through 2002. Ann. Intern. Med. 2006, 144: 705-714.
  4. Durham D.P., Skrip L.A., Bruce R.D. et al. The impact of enhanced screening and treatment on hepatitis C in the United States. Clin. Infect. Dis. 2016,62 (3): 298-304. doi: 10.1093/cid/ civ894.
  5. Deuffic-Burban S., Deltenre P, Buti M. et al. Predicted effects of treatment for HCV infection vary among European countries. Gastroenterology. 2012, 143 (4): 974-985.
  6. Gonzalez-Grande R., Jimenez-Perez M., Gonzalez Arjona C., Mostazo Torres J. New approaches in the treatment of hepatitis C. World J. Gastroenterol. 2016, 22 (4): 1421-32. doi: 10.3748/wjg.v22.i4.1421.
  7. Global health sector strategy on viral hepatitis 2016-2021. World Health Organization, 2016. http://apps.who.int/iris/bitstream/10665/246177/l/WHO-HIV-2016.06-eng.pdf.
  8. Lanini S., Easterbrook P.J., Zumla A., Ippolito G. hepatitis c: global epidemiology and strategies for control. Clin. Microbiol. Infect. 2016, Aug 10. pii: S1198-743X(16)30300-7. doi: 10.1016/j.cmi.2016.07.035.
  9. Lemoine M., Nayagam S., Thursz M. Viral hepatitis in resource-limited countries and access to antiviral therapies: current and future challenges. Future Virol. 2013, 8 (4): 371-380.
  10. McGarry L.J., PawarV.S., PanchmatiaH.R. et al. Economic model of a birth cohort screening program for hepatitis C virus. Hepatology. 2012, 55 (5): 1344-1355.
  11. Mohd Hanafiah K., Groeger J., Flaxman A.D., Wiersma S.T. Global epidemiology of hepatitis C virus infection: new estimates of age-specific antibody to HCV seroprevalence. Hepatology. 2013,57(4): 1333-1342.
  12. Smith B.D., Morgan R.L., Beckett G.A. et al. Centers for Disease Control and Prevention (CDC). Recommendations for the identification of chronic hepatitis C virus infection among persons bom during 1945-1965. MMWRRecomm. Rep. 2012,61 (No. RR-4): 1-32. Erratum in: MMWR Recomm Rep. 2012, 61: 886.
  13. Wasley A., Alter M. J. Epidemiology of hepatitis C: geographic differences and temporal trends. Semin Liver Dis. 2000, 20: 1-16.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright (c) 2017 Soboleva N.V., Karlsen A.A., Kozhanova T.V., Kichatova V.S., Klushkina V.V., Isaeva O.V., Ignatyeva M.E., Romanenko V..., Oorzhak N.D., Malinnikova E.Y., Kyuregyan K.K., Mikhaylov M.I.

Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.
СМИ зарегистрировано Федеральной службой по надзору в сфере связи, информационных технологий и массовых коммуникаций (Роскомнадзор).
Регистрационный номер и дата принятия решения о регистрации СМИ: ПИ № ФС77-75442 от 01.04.2019 г.


This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies